| Self-stabilizing linker conjugates |
2023-5-15 |
2023-6-01 |
|
| Combination Therapy |
2023-4-28 |
2023-8-31 |
|
| Uveal melanoma treatment using sea-cd40 |
2023-3-29 |
2023-8-17 |
|
| Multi-drug antibody drug conjugates |
2023-3-10 |
2023-5-23 |
|
| Glycan-interacting compounds and methods of use |
2023-3-07 |
2023-5-09 |
|
| Hydrophilic antibody-drug conjugates |
2023-3-06 |
2023-4-06 |
|
| Antibodies to integrin avb6 and use of same to treat cancer |
2023-2-17 |
2023-8-03 |
|
| Process for preparing tubulysin and intermediates thereof |
2023-2-16 |
2023-4-12 |
|
| Methylene carbamate linkers for use with targeted-drug conjugates |
2023-2-14 |
2023-4-18 |
|
| Targeted delivery of nicotinamide adenine dinucleotide salvage pathway … |
2023-1-26 |
2023-3-16 |
|
| Methods for treating muscle invasive urothelial cancer or muscle invasive … |
2023-1-04 |
2023-7-13 |
|
| Drug conjugates with self-stabilizing linkers having improved physiochemical … |
2022-11-24 |
2023-1-05 |
|
| Methods of treating her2 positive cancer with tucatinib in combination with … |
2022-11-24 |
2023-1-01 |
|
| Anti-ntb-a antibodies and related compositions and methods |
2022-11-23 |
2023-7-13 |
|
| Dosage and administration of non-fucosylated anti-cd40 antibody |
2022-11-09 |
2023-6-29 |
|
| Methods of treating cancer with a combination of an anti-pd-1 antibody and an … |
2022-10-27 |
2023-5-04 |
|
| Humanized antibodies to liv-1 and use thereof to treat cancer |
2022-10-25 |
2023-1-24 |
|
| Combination therapy using a liv1-adc and a chemotherapeutic |
2022-10-17 |
2023-7-27 |
|
| Modulating the immune response using antibody-drug conjugates |
2022-10-17 |
2023-9-07 |
|
| Charge variant linkers |
2022-10-06 |
2022-12-01 |
|
| ANTIBODY-DRUG CONJUGATE (ADC) BINDING TO 191P4D12 PROTEIN |
2022-10-05 |
2022-12-09 |
|
| Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor … |
2022-10-05 |
2022-11-17 |
|
| B7-h4 antibody-drug conjugates for the treatment of cancer |
2022-9-29 |
2023-4-06 |
|
| Treatment of HER2 positive cancers |
2022-9-28 |
2022-10-27 |
|
| Improved antibody masking domains |
2022-9-23 |
2023-3-30 |
|
| Methods of treating multiple myeloma |
2022-9-21 |
2022-11-01 |
|
| Methods of treating multiple myeloma |
2022-9-20 |
2023-3-30 |
|
| Use of anti-pd-1 antibody in combination with anti-cd30 antibody in lymphoma … |
2022-8-18 |
2022-11-30 |
|
| Anti-ntb-a antibodies and related compositions and methods |
2022-8-15 |
2023-4-06 |
|
| Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody … |
2022-8-12 |
2023-4-16 |
|
| Glycan-interacting compounds and methods of use |
2022-8-10 |
2022-10-19 |
|
| Selective reduction of proteins |
2022-8-05 |
2022-10-12 |
|
| Treatment for cancer |
2022-7-29 |
2023-4-01 |
|
| Anti-tigit antibodies |
2022-7-26 |
2022-9-29 |
|
| β-GLUCURONIDE-LINKER DRUG CONJUGATE |
2022-7-22 |
2022-9-21 |
|
| Use of antibody drug conjugates comprising tubulin disrupting agents to treat … |
2022-7-21 |
2023-4-13 |
|
| Antibody masking domains |
2022-7-13 |
2023-1-19 |
|
| PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
2022-6-30 |
2022-7-21 |
|
| Methods of treating cancer with a combination of a nonfucosylated anti-cd70 … |
2022-6-28 |
2023-1-05 |
|
| Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
2022-6-23 |
2022-8-01 |
|
| Glycan-Interacting Compounds and Methods of Use |
2022-6-22 |
2023-5-11 |
|
| Anti-TIGIT Antibodies |
2022-6-10 |
2023-2-16 |
|
| Targeted delivery of tertiary amine-containing drug substances |
2022-6-09 |
2022-6-30 |
|
| Anthracycline antibody conjugates |
2022-5-27 |
2023-4-01 |
|
| Methods of quantifying anti-cd40 antibodies |
2022-5-25 |
2022-12-01 |
|
| Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates |
2022-5-24 |
2023-1-24 |
2023-1-24 |
| Conjugates of quaternized tubulysin compounds |
2022-5-24 |
2022-7-14 |
|
| Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 … |
2022-5-22 |
2022-7-01 |
|
| Anti-avb6 antibodies and antibody-drug conjugates |
2022-5-22 |
2022-7-01 |
|
| Detection and treatment of cd30+ cancers |
2022-5-18 |
2022-11-24 |
|
| High performance liquid chromatography quantification of excipients |
2022-5-17 |
2022-7-01 |
|
| Methods of treating her2 positive breast cancer with tucatinib in combination … |
2022-5-09 |
2022-7-01 |
|
| Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv … |
2022-5-02 |
2022-7-01 |
|
| Process for the preparation of glucuronide drug-linkers and intermediates … |
2022-5-01 |
2022-7-01 |
|
| Glycan-interacting compounds and methods of use |
2022-4-27 |
2022-8-17 |
|
| Modulation of antibody-dependent cellular cytotoxicity |
2022-4-20 |
2023-2-01 |
|
| Methods of treating her2 positive breast cancer with tucatinib in combination … |
2022-4-18 |
2022-6-01 |
|
| Methods of treating cancer with anti-tigit antibodies |
2022-4-08 |
2022-10-13 |
|
| Process for preparation of pegylated drug linkers and intermediates thereof |
2022-4-08 |
2022-6-02 |
|
| Camptothecin peptide conjugates |
2022-3-24 |
2022-5-01 |
|
| Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine … |
2022-3-24 |
2022-9-29 |
|
| Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of … |
2022-3-22 |
2022-5-01 |
|
| Anti-pd-l1 antibodies and antibody-drug conjugates |
2022-3-21 |
2022-5-01 |
|
| Methods and compositions for making antibodies and antibody derivatives with … |
2022-3-18 |
2023-2-23 |
|
| Anti-alpp/alppl2 antibodies and antibody-drug conjugates |
2022-3-17 |
2023-6-29 |
|
| Selective drug release from internalized conjugates of biologically active … |
2022-3-17 |
2023-1-01 |
|
| Selective drug release from internalized conjugates of biologically active … |
2022-3-17 |
2023-3-23 |
|
| SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE … |
2022-3-17 |
2023-6-14 |
|
| ANTI-ALPP / ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
2022-3-17 |
2023-6-14 |
|
| SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE … |
2022-3-17 |
2023-6-14 |
|
| Selective drug release from internalized conjugates of biologically active … |
2022-3-17 |
2022-9-22 |
|
| Selective drug release from internalized conjugates of biologically active … |
2022-3-17 |
2022-9-22 |
|
| Compositions and Methods for Targeting Cancer Stem Cells |
2022-3-16 |
2023-1-26 |
|
| Compositions and Methods for Targeting Cancer Stem Cells |
2022-3-16 |
2023-1-26 |
|
| Selective drug release from internalized conjugates of biologically active … |
2022-3-16 |
2022-5-01 |
|
| Cd19 binding agents and uses thereof |
2022-3-08 |
2023-2-02 |
|
| Bcma antibiotics and use thereof for treating cancer and immunological … |
2022-3-01 |
2022-5-11 |
|
| Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 … |
2022-2-07 |
2022-4-01 |
|
| Immunostimulatory compounds and conjugates |
2022-2-07 |
2022-11-01 |
|
| IMMUNOMODULATOR ANTIBODY-DRUG CONJUGATES |
2022-1-14 |
2023-4-19 |
|
| Immunomodulatory antibody-drug conjugates |
2022-1-14 |
2023-7-27 |
|
| Humanized anti-liv1 antibodies for the treatment of cancer |
2022-1-13 |
2022-3-01 |
|
| Modulating the immune response using anti-cd30 antibody-drug conjugates |
2021-12-02 |
2022-6-09 |
|
| Methods of treating cancer with a combination of tucatinib and an anti-pd-1/ … |
2021-11-16 |
2023-6-29 |
|
| Combination-therapy antibody drug conjugate with immune cell inhibitor |
2021-11-05 |
2022-5-12 |
|
| Camptothecin peptide conjugates |
2021-10-27 |
2022-6-23 |
|
| Cyclodextrin and antibody-drug conjugate formulations |
2021-10-25 |
2021-12-01 |
|
| CD47 Antibodies and Uses Thereof for Treating Cancer |
2021-10-20 |
2022-5-05 |
|
| Methods for treating cancers with antibody drug conjugates (adc) that bind to … |
2021-10-08 |
2022-8-01 |
|
| HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER |
2021-9-28 |
2022-12-28 |
|
| Methods of treating solid tumors driven by her2 alterations with tucatinib in … |
2021-9-27 |
2022-3-31 |
|
| Humanized anti-liv1 antibodies for the treatment of cancer |
2021-9-27 |
2022-6-30 |
|
| Methods for treating cancers with antibody drug conjugates (adc) that bind to … |
2021-9-16 |
2022-3-24 |
|
| ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
2021-8-04 |
2023-4-12 |
|
| Methods of treating her2 positive cancer with tucatinib in combination with … |
2021-7-28 |
2023-3-01 |
|
| Methods and systems for producing polypeptides |
2021-7-27 |
2023-6-07 |
|
| Anti-cd228 antibodies and antibody-drug conjugates |
2021-7-19 |
2021-9-30 |
|
| Methods of treating breast cancer with tucatinib |
2021-7-14 |
2021-8-31 |
|
| Markers for use in methods for treating cancers with antibody drug conjugates ( … |
2021-6-18 |
2021-12-23 |
|
| Adcs with thiol multiplex linkers |
2021-6-17 |
2021-8-31 |
|